<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583621</url>
  </required_header>
  <id_info>
    <org_study_id>pro#00000051</org_study_id>
    <nct_id>NCT01583621</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)</brief_title>
  <acronym>D-SUNNY</acronym>
  <official_title>Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augusta University</source>
  <brief_summary>
    <textblock>
      Primary Specific Aim 1: To compare the dose-responsive effects of vitamin D3 supplementations
      on 25(OH) D, parathyroid hormone (PTH), and serum/urine calcium.

      Primary Specific Aim 2: To compare the dose-responsive effects of vitamin D3 supplementations
      on non-invasive vascular measures including pulse wave velocity (PWV), flow-mediated dilation
      (FMD), carotid arterial compliance (CAC), carotid Intima-Media Thickness (cIMT), and 24-hours
      Ambulatory Blood Pressure (ABP) monitoring as well as casual BP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular phenotypes</measure>
    <time_frame>16 weeks</time_frame>
    <description>Will be using non-invasive vascular measures including pulse wave velocity (PWV), flow-mediated dilation (FMD), carotid arterial compliance (CAC), carotid Intima-Media Thickness (cIMT), and 24-hours Ambulatory Blood Pressure (ABP) monitoring.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary outcome 1 dose-responsive effects of vitamin D3 supplementations</measure>
    <time_frame>16 weeks</time_frame>
    <description>To compare the dose-responsive effects of vitamin D3 supplementations on 25(OH) D, parathyroid hormone (PTH), and serum/urine calcium.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome 2 dose-responsive effects of vitamin D3 supplementations</measure>
    <time_frame>16 weeks</time_frame>
    <description>To compare the dose-responsive effects of vitamin D3 supplementations on non-invasive vascular measures including pulse wave velocity (PWV), flow-mediated dilation (FMD), carotid arterial compliance (CAC), carotid Intima-Media Thickness (cIMT), and 24-hours Ambulatory Blood Pressure (ABP) monitoring as well as casual BP.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplementation arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cholecalciferol 18000 U/month for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>supplementation arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cholecalciferol 60000 U/month for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplementation arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cholecalciferol 120000 U/month for 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).</description>
    <arm_group_label>Supplementation arm 1</arm_group_label>
    <arm_group_label>supplementation arm 2</arm_group_label>
    <arm_group_label>Supplementation arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. African-Americans (blacks)

          2. Age 13-45

          3. Overweight/obese (BMI ≥ 85th percentile for their age and gender for age 13-17 and BMI
             ≥ 25 kg/m2 for age 18-45)

          4. Relatively healthy (no medical history of any heart, lung, endocrine or malignant
             disorder)

          5. Non pregnant

          6. Not on any medication or vitamin supplements that can influence the study outcomes

          7. Serum 25 hydroxy Vitamin D (25[OH] D) levels ≤ 20 ng/ml (50 nmol/L) at the time of
             screening

        Exclusion Criteria:

          1. Not meeting any one or more of the above criteria

          2. Females who become pregnant/test positive on urine pregnancy test during the screening
             or any of the testing visits

          3. Anyone who is taking any multivitamin supplements that contains vitamin D
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanbin Dong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgia Prevention Institute</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2012</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Yanbin Dong</investigator_full_name>
    <investigator_title>Professor, Department of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

